Comparison of Therapeutic Outcomes: Two Triple-Therapy Approaches for H. pylori Eradication in Gastric Ulcer Disease
Two Triple-Therapy for H. pylori Eradication
DOI:
https://doi.org/10.54393/pjhs.v5i07.1850Keywords:
Standard Triple Therapy, Gastric Ulcer, Helicobacter pylori, Antibiotic ResistanceAbstract
Gastric ulcer is a prevalent digestive disease, primarily caused by Helicobacter pylori infection. H. pylori infection poses a substantial challenge for medical practitioners due to increased antibiotic resistance. Objectives: To compare the efficacy of a 14-days clarithromycin-based triple therapy (TRT) with a moxifloxacin-based TRT for eradicating Helicobacter pylori in gastric ulcer disease. Methods: A quasi experimental study was conducted with 294 positive H. pylori patients divided into two groups. Group A was given standard triple therapy while Group B received moxifloxacin-based triple therapy. Data collection commenced after obtaining IRB approval and informed consent from all participants. Descriptive statistics was used to calculate frequency and percentages. Differences between the two groups were compared using the fisher exact analysis at a significance level, p-value < 0.05. Results: In the group with standard triple therapy (TRT), the eradication rates of H. pylori were reported as 67.3 % intention-to-treat (ITT) and 76.1% per-protocol (PP) analysis. In contrast, in the moxifloxacin-based triple therapy (MAO) group, the eradication rates were 86.3% ITT and 92.7% PP analysis. The eradication rates with moxifloxacin-containing triple therapy were statistically significant than standard TRT (p = 0.001). Furthermore, few side effects were evident in the moxifloxacin TRT group (p < 0.001) compared to the standard TRT group. Conclusions: In Pakistan, moxifloxacin-containing triple therapy may offer a notably superior treatment option for eradicating H. pylori infection compared to standard triple therapy.
References
Salari N, Darvishi N, Shohaimi S, Bartina Y, Ahmadipanah M, Salari HR et al. The global prevalence of peptic ulcer in the world: A systematic review and meta-analysis. Indian Journal of Surgery. 2022 Oct; 84(5): 913-21. doi: 10.1007/s12262-021-03189-z. DOI: https://doi.org/10.1007/s12262-021-03189-z
Den Hoed CM and Kuipers EJ. 45-Helicobacter pylori infection. In Hunter's Tropical Medicine and Emerging Infectious Diseases. 2020 Jan; 476-480. doi: 10.1016/B978-0-323-55512-8.00045-4. DOI: https://doi.org/10.1016/B978-0-323-55512-8.00045-4
Hassan MN, Arif A, Shahzad MS, Ibrahim M, Rahman HA, Razaq MA et al. 88. Global prevalence of Helicobacter pylori and its effect on human health. Pure and Applied Biology (PAB). 2020 Feb; 9(1): 936-48. doi: 10.19045/bspab.2020.90098. DOI: https://doi.org/10.19045/bspab.2020.90098
Haq I, Muhammad A, Fazli Zahir MK, Anwar F, Akhtar MS, Ullah F. Serological and Epidemiology study of Helicobacter pylori infection among Dyspeptic patients in District Peshawar Pakistan. Advances in Bioresearch. 2020 May; 11(3): 81-5. doi: 10.15515/abr.0976-4585.11.3.8185.
Shah SR, Almugadam BS, Hussain A, Ahmad T, Ahmed S, Sadiqui S. Epidemiology and risk factors of Helicobacter pylori infection in Timergara city of Pakistan: a cross-sectional study. Clinical Epidemiology and Global Health. 2021 Oct; 12: 100909. doi: 10.1016/j.cegh.2021.100909. DOI: https://doi.org/10.1016/j.cegh.2021.100909
De Brito BB, da Silva FA, Soares AS, Pereira VA, Santos ML, Sampaio MM et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World Journal of Gastroenterology. 2019 Oct; 25(37): 5578. doi: 10.3748/wjg.v25.i37.5578. DOI: https://doi.org/10.3748/wjg.v25.i37.5578
Razuka-Ebela D, Polaka I, Parshutin S, Santare D, Ebela I, Murillo R et al. Sociodemographic, lifestyle and medical factors associated with Helicobacter pylori infection. Journal of Gastrointestinal & Liver Diseases. 2020 Sep; 29(3). 319-327. doi: 10.15403/jgld-870. DOI: https://doi.org/10.15403/jgld-870
Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N et al. Helicobacter pylori infection: current status and future prospects on diagnostic, therapeutic and control challenges. Antibiotics. 2023 Jan; 12(2): 191. doi: 10.3390/antibiotics12020191. DOI: https://doi.org/10.3390/antibiotics12020191
Muhammad N, Afridi J, Mahmood N, Ali S. Frequency of Helicobacter pylori in stool specimens of patients suspected of upper gastrointestinal symptoms in District Bunir. Jundishapur Journal of Microbiology. 2020 Aug; 13(8): e104471. doi: 10.5812/jjm.104471. DOI: https://doi.org/10.5812/jjm.104471
O'Connor A, Furuta T, Gisbert JP, O'Morain C. Review–treatment of Helicobacter pylori infection 2020. Helicobacter. 2020 Sep; 25: e12743. doi: 10.1111/hel.12743. DOI: https://doi.org/10.1111/hel.12743
Moss SF, Chey WD, Daniele P, Pelletier C, Jacob R, Tremblay G et al. Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology. 2023 Jun; 16: 17562848231167284. doi: 10.1177/17562848231167284. DOI: https://doi.org/10.1177/17562848231167284
Mori H and Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World Journal of Gastroenterology. 2020 Apr; 26(15): 1733. doi: 10.3748/wjg.v26.i15.1733. DOI: https://doi.org/10.3748/wjg.v26.i15.1733
Kong S, Huang K, Wang J, Wang X, Yang N, Dong Y et al. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. Gut Pathogens. 2020 Dec; 12: 1-9. doi: 10.1186/s13099-020-00378-1. DOI: https://doi.org/10.1186/s13099-020-00378-1
Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019 Jul; 157(1): 44-53. doi: 10.1053/j.gastro.2019.04.011. DOI: https://doi.org/10.1053/j.gastro.2019.04.011
Gisbert JP. Optimization strategies aimed to increase the efficacy of Helicobacter pylori eradication therapies with quinolones. Molecules. 2020 Nov; 25(21): 5084. doi: 10.3390/molecules25215084. DOI: https://doi.org/10.3390/molecules25215084
Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infectious Diseases. 2019 Dec; 19: 1-7. doi: 10.1186/s12879-019-4085-1. DOI: https://doi.org/10.1186/s12879-019-4085-1
Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ et al. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA® GENE Helicobacter pylori assay. Acta Clinica Belgica. 2021 May; 76(3): 177-83. doi: 10.1080/17843286.2019.1685741. DOI: https://doi.org/10.1080/17843286.2019.1685741
Shrestha AB, Pokharel P, Sapkota UH, Shrestha S, Mohamed SA, Khanal S et al. Drug resistance patterns of commonly used antibiotics for the treatment of Helicobacter pylori infection among South Asian countries: a systematic review and meta-analysis. Tropical Medicine and Infectious Disease. 2023 Mar; 8(3): 172. doi: 10.3390/tropicalmed8030172. DOI: https://doi.org/10.3390/tropicalmed8030172
Bilal H, Khan MN, Rehman T, Hameed MF, Yang X. Antibiotic resistance in Pakistan: a systematic review of past decade. BMC Infectious Diseases. 2021 Dec; 21: 1-9. doi: 10.1186/s12879-021-05906-1. DOI: https://doi.org/10.1186/s12879-021-05906-1
Ahmed MH, Abd-Elsalam S, Mahrous AM. Moxifloxacin based triple therapy as alternative to standard therapy in Helicobacter Pylori Eradication. Anti-Infective Agents. 2021 Jun; 19(3): 299-302. doi: 10.2174/2211352518999200925154501. DOI: https://doi.org/10.2174/2211352518999200925154501
Akpinar M, Aksoy E, Sapmaz F, Goktas Z, Uzman M, Nazligul Y. Comparison of moxifloxacin-based therapies and standard bismuth-based quadruple therapy for first-line treatment of Helicobacter pylori infection. Archives of Medical Science-Civilization Diseases. 2018 Oct; 3(1): 81-6. doi: 10.5114/amscd.2018.78766. DOI: https://doi.org/10.5114/amscd.2018.78766
Hassan AM, Eid K, Eliwa KA, Abdel-Gawad M. Two nitazoxanide-based quadruple regimens for eradication of Helicobacter pylori infection: a single-center randomized controlled trial. Al-Azhar Assiut Medical Journal. 2022 Jan; 20(1): 67-71. doi: 10.4103/azmj.azmj_74_21 DOI: https://doi.org/10.4103/azmj.azmj_74_21
Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World Journal of Gastroenterology. 2015 Apr; 21(16): 5032-8. doi: 10.3748/wjg.v21.i16.5032. DOI: https://doi.org/10.3748/wjg.v21.i16.5032
Kadhim AM, Mohammed MM, Abdul-Hussein HM. Treatment of Helicobacter pylori Infections Using Moxifloxacin-Triple Therapy Compared to Standard Triple and Quadruple Therapies. Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2023 Jun; 32(1): 107-14. doi: 10.31351/vol32iss1pp107-114. DOI: https://doi.org/10.31351/vol32iss1pp107-114
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
